Sirnaomics and Gore Range Capital Partner to Launch Sagesse Bio, an Aesthetic Medicine Company

Sirnaomics Ltd., a leading biopharmaceutical company, and Gore Range Capital LLC have announced a partnership to establish Sagesse Bio, Inc., a joint venture poised to transform the aesthetic medicine industry. Sagesse Bio will harness the power of RNAi therapeutics to develop innovative products for body contouring and fat reduction.

The partnership combines Sirnaomics’ expertise in RNAi-based technology and product development with Gore Range Capital’s extensive knowledge in skin health and financial resources. Sagesse Bio will accelerate the clinical development of Sirnaomics’ lead compound, currently in Phase II clinical trials, and leverage the expertise of its founders, board of directors, and executive management team.

Frederick Beddingfield, MD, PhD, Chairperson of Sagesse Bio’s board of directors, expressed excitement about the venture, citing the potential for rapid advancement of the company’s lead product. Humberto Antunes, co-founder of Sagesse Bio and partner of Gore Range Capital, emphasized the company’s strategic goal of delivering innovative therapies to patients.

Dr. Patrick Lu, founder and CEO of Sirnaomics, hailed the partnership as a historic opportunity to bring RNAi therapeutic candidates into medical aesthetic product development. Under the partnership, Sagesse Bio will initiate clinical evaluation of its lead product candidate, SGY-101, with support from Sirnaomics, and Sirnaomics will receive milestone payments and a majority equity position in Sagesse Bio.

Gore Range Capital will provide initial funding, build the executive management team and advisory board, and offer hands-on support for fundraising and business development. The partnership is subject to shareholder approval at an upcoming general meeting.

Source

Also Read:

Sofinnova Partners secures USD 200Mln digital medicine fund

Janux Therapeutics designates Zachariah McIver as Vice President, Clinical Development